Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of Tegavivint (NSC#826393) in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

NCT04851119 is registered in ClinicalTrials.gov with Children's Oncology Group as lead sponsor.

NCT NCT04851119
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04851119 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of Tegavivint (NSC#826393) in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Lead sponsor
Children's Oncology Group
Phase
Phase 1/2
Overall status
Recruiting
Start date
November 8, 2021
Completion date
June 30, 2028
Enrollment
147 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal carcinoma, endometrial carcinoma, melanoma, neuroblastoma, ovarian carcinoma, pancreatic ductal adenocarcinoma, recurrent desmoid fibromatosis, recurrent ewing sarcoma, recurrent hepatoblastoma, recurrent hepatocellular carcinoma, recurrent malignant solid neoplasm, recurrent non-hodgkin lymphoma, recurrent osteosarcoma, refractory desmoid fibromatosis, refractory ewing sarcoma, refractory hepatoblastoma, refractory hepatocellular carcinoma, refractory malignant solid neoplasm, refractory non-hodgkin lymphoma, refractory osteosarcoma, solid pseudopapillary neoplasm of the pancreas, wilms tumor